OBJECTIVE: To determine the prophylactic effect of oral acyclovir on the recurrence rate of herpetic eye disease after penetrating keratoplasty.
DESIGN: A randomized, double-masked, placebo-controlled multicenter trial.
PARTICIPANTS: Sixty-eight consecutive patients (68 eyes) with corneal opacities due to herpetic eye disease who underwent penetrating keratoplasty.
INTERVENTION: Oral acyclovir 400 mg twice daily or placebo tablets for 6 months.
MAIN OUTCOME MEASURES: The recurrence rate of herpetic eye disease-related events and rejection episodes, proven by viral cell culture or polymerase chain reaction.
RESULTS: During the 2-year follow-up period, there were 3 culture-proven herpetic eye disease recurrences in the acyclovir group and 9 in the placebo group. Lifetime survival analysis of the probability of remaining free from recurrence revealed a significantly reduced risk of recurrent herpetic disease in the acyclovir-treated group.
CONCLUSION: This study suggests that oral acyclovir effectively prevents herpes-related recurrences after penetrating keratoplasty in herpetic eye disease.
|Pages (from-to)||1916-9; discussion 1919|
|Publication status||Published - Oct 2003|
- Acyclovir/administration & dosage
- Administration, Oral
- Antiviral Agents/administration & dosage
- Corneal Opacity/surgery
- Double-Blind Method
- Graft Rejection/prevention & control
- Keratitis, Herpetic/prevention & control
- Keratoplasty, Penetrating
- Middle Aged
- Postoperative Complications/prevention & control
- Secondary Prevention